Sherbrooke Park Advisers LLC Sells 12,897 Shares of Annexon, Inc. (NASDAQ:ANNX)

Sherbrooke Park Advisers LLC reduced its holdings in shares of Annexon, Inc. (NASDAQ:ANNX) by 30.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 30,134 shares of the company’s stock after selling 12,897 shares during the quarter. Sherbrooke Park Advisers LLC’s holdings in Annexon were worth $155,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. Sphera Funds Management LTD. bought a new stake in shares of Annexon in the fourth quarter valued at $6,377,000. Ameriprise Financial Inc. raised its stake in shares of Annexon by 483.6% in the fourth quarter. Ameriprise Financial Inc. now owns 926,642 shares of the company’s stock valued at $4,754,000 after buying an additional 767,869 shares during the period. Vanguard Group Inc. raised its stake in shares of Annexon by 11.6% in the fourth quarter. Vanguard Group Inc. now owns 5,546,918 shares of the company’s stock valued at $28,456,000 after buying an additional 576,625 shares during the period. Mutual of America Capital Management LLC raised its stake in shares of Annexon by 56.2% in the fourth quarter. Mutual of America Capital Management LLC now owns 1,029,680 shares of the company’s stock valued at $5,282,000 after buying an additional 370,426 shares during the period. Finally, Candriam S.C.A. raised its stake in shares of Annexon by 15.6% in the fourth quarter. Candriam S.C.A. now owns 2,534,230 shares of the company’s stock valued at $13,001,000 after buying an additional 341,431 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Needham & Company LLC lowered their target price on Annexon from $16.00 to $11.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th. HC Wainwright lowered their target price on Annexon from $20.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th.

Annexon Stock Performance

Shares of NASDAQ ANNX opened at $2.10 on Wednesday. The stock has a market cap of $230.40 million, a PE ratio of -2.00 and a beta of 1.24. Annexon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85. The stock has a fifty day moving average of $1.89 and a 200-day moving average of $3.58.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.07). On average, sell-side analysts predict that Annexon, Inc. will post -0.96 EPS for the current year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.